Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! View ALL results for your Stocks, ETFs and Funds Screeners with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Doubleline Securitized Credit ETF (DSCO)

Doubleline Securitized Credit ETF (DSCO)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE Arca]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE Arca]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Profile for [[ item.sessionDateDisplayLong ]]

Company Info

Doubleline Securitized Credit ETF 2600 KELLY ROAD SUITE 100 WARRINGTON PA 18976-3622

www.discoverylabs.com P: 215-488-9300

Sector:

Medical

INDUSTRY GROUPING:

Medical - Biomedical

Description:

Discovery Laboratories, Inc., formerly known as Ansan Pharmaceuticals, Inc., is a development-stage pharmaceutical company that focuses on developing compounds to treat respiratory diseases that affect the ability of the lungs to absorb oxygen. It is initially developing its lead product candidate, Surfaxin, for use by newborn infants to treat two respiratory conditions in critical care units of hospitals. The second compound under development is SuperVent, which is intended to treat airway diseases such as cystic fibrosis (CF) and chronic bronchitis.

Key Statistics

Overview:

Market Capitalization, $K 31,620
Shares Outstanding, K 8,150
Short Interest, K 12
Short Float 0.00%
Days to Cover 1.00
Short Volume Ratio 0.83
% of Insider Shareholders 3.28%

Financials:

Annual Sales, $ 990 K
Annual Net Income, $ -55,170 K
Last Quarter Sales, $ 660 K
Last Quarter Net Income, $ -10,110 K

Growth:

1-Year Return -0.86%
3-Year Return 0.00%
5-Year Return 0.00%
5-Year Revenue Growth 0.00%
5-Year Earnings Growth -73.04%
5-Year Dividend Growth 0.00%

Per-Share Information:

Next Earnings Date 05/05/16
Earnings Per Share ttm -6.30
EPS Growth vs. Prev Qtr 0.04%
EPS Growth vs. Prev Year 47.08%
Annual Dividend & Yield (Paid) 0.00 (0.00%)
Annual Dividend & Yield (Fwd) 0.00 (0.00%)
Next Ex-Dividends Date 04/01/26
Dividend Payable Date 04/08/26
Dividend Payout Ratio 0.00%
Most Recent Split 1-14 on 01/22/16

DSCO Ratios

Ratio
Price/Earnings ttm 0.00
Price/Earnings forward N/A
Price/Earnings to Growth N/A
Return-on-Equity % -562.15%
Return-on-Assets % -106.26%
Profit Margin % -5,572.73%
Debt/Equity 3.02
Price/Sales 17.70
Price/Cash Flow N/A
Price/Book 3.45
Book Value/Share 1.01
Interest Coverage 0.00
60-Month Beta 1.65

DSCO Dividends

Date Value
04/01/26 $0.1150
03/02/26 $0.1120
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.